Groowe Groowe BETA / Newsroom
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

RYTELO (Imetelstat) Clinical, Regulatory and Commercial Intelligence Report 2026-2034

globenewswire.com
GERN Geron Corporation reported increased net product revenue for RYTELO, with demand and ordering accounts rising. The drug showed positive real-world evidence and consistent efficacy in clinical studies, suggesting potential for long-term revenue growth.

RYTELO (Imetelstat) Clinical, Regulatory and Commercial Intelligence Report 2026-2034 Dublin, Sept. 09, 2026 (GLOBE NEWSWIRE) -- The "RYTELO Sales Forecast, and Market Size Analysis - 2034" has been added to ResearchAndMarkets.com's offering.

The report provides a comprehensive assessment of RYTELO (imetelstat) across approved and potential hematologic indications in the seven major markets (7MM): the United States, Germany, France, Italy, Spain, the United Kingdom, and Japan. The analysis covers historical performance, current utilization, market dynamics, competitive positioning, pricing, regulatory milestones, and sales forecasts through 2034.

Key Factors Driving RYTELO Market Growth

Recent RYTELO Developments

In August 2026, Geron Corporation reported RYTELO net product revenue of $57.5 million for the second quarter of 2026. Demand increased by 5% compared with the first quarter, while ordering accounts rose by approximately 8% to about 1,575.

Geron also presented the first real-world evidence study of RYTELO in lower-risk MDS at the European Hematology Association 2026 Congress. The retrospective investigator-sponsored study from Moffitt Cancer Center evaluated patients with advanced, heavily transfusion-dependent LR-MDS, including individuals who had received multiple previous therapies or experienced luspatercept failure. Reported efficacy, safety, and tolerability were generally consistent with the Phase III IMerge findings in a broader patient population.

RYTELO Clinical and Product Overview

RYTELO is administered by intravenous infusion every four weeks. Its U.S. indication covers adults with low- to intermediate-1-risk MDS and transfusion-dependent anemia requiring four or more red blood cell units over eight weeks who have not responded to, have lost response to, or are ineligible for ESAs.

The treatment demonstrated clinically meaningful and durable transfusion independence in the IMerge trial. Important safety considerations include thrombocytopenia, neutropenia, anemia, fatigue, and elevated liver enzymes, requiring hematologic and hepatic monitoring during treatment.

Scope of the RYTELO Market Report

RYTELO Competitive and Commercial Analysis

The report evaluates RYTELO's market positioning against established treatments and emerging therapies for lower-risk MDS, myelofibrosis, and other potential hematologic indications. It assesses efficacy, safety, clinical differentiation, prescribing trends, peak sales potential, and the potential effect of new product launches on RYTELO market share.

The analysis also examines commercial partnerships, licensing agreements, mergers and acquisitions, regulatory designations, reimbursement conditions, and factors influencing adoption. Increased ordering accounts, growing real-world experience, international expansion, and potential label extensions may support long-term RYTELO revenue growth, while competition, treatment costs, safety monitoring, and pipeline innovation remain important market considerations.

Research Methodology

The RYTELO market forecast is based on internal databases, primary research, secondary research, and analysis by industry experts. Sources include regulatory authority publications, clinical trial registries, company disclosures, medical congress presentations, peer-reviewed journals, trade associations, industry databases, white papers, and healthcare news sources.

Key Questions Addressed

The report delivers an integrated view of RYTELO's clinical profile, commercial performance, competitive environment, and long-term market potential, supporting strategic planning and therapeutic portfolio decisions across the global hematology market.

Key Topics Covered

1. Report Introduction

2. RYTELO Overview in approved indications like Myelodysplastic syndrome; as well as potential indication like Acute myeloid leukaemia and Myelofibrosis

2.1. Product Detail

2.2. RYTELO Clinical Development

2.2.1. RYTELO Clinical studies

2.2.2. RYTELO Clinical trials information

2.2.3. Safety and efficacy

2.3. Other Developmental Activities

2.4. Product Profile

3. RYTELO Competitive Landscape (Marketed Therapies)

4. Competitive Landscape (Late-stage Emerging RYTELO Therapies)

5. RYTELO Market Assessment

5.1. RYTELO Market Outlook in approved and potential indications

5.2. 7MM Analysis

5.2.1. RYTELO Market Size in the 7MM for approved and potential indications

5.3. Country-wise Market Analysis

5.3.1. RYTELO Market Size in the United States for approved and potential indications

5.3.2. RYTELO Market Size in Germany for approved and potential indications

5.3.3. RYTELO Market Size in France for approved and potential indications

5.3.4. RYTELO Market Size in Italy for approved and potential indications

5.3.5. RYTELO Market Size in Spain for approved and potential indications

5.3.6. RYTELO Market Size in the United Kingdom for approved and potential indications

5.3.7. RYTELO Market Size in Japan for approved and potential indications

6. RYTELO SWOT Analysis

7. Analyst's Views

8. Appendix

8.1. Bibliography

8.2. Report Methodology

List of Tables

Table 1: RYTELO, Clinical Trial Description, 2023

Table 2: RYTELO, General Description

Table 3: Competitive Landscape (Marketed Therapies)

Table 4: Competitive Landscape (Emerging Therapies)

Table 5: RYTELO's pricing and cost Assumptions

Table 6: RYTELO's Sales Analysis in the 7MM, in USD million (2020-2034)

Table 7: RYTELO Market Size in the US, in USD million (2020-2034)

Table 8: RYTELO Market Size in Germany, in USD million (2020-2034)

Table 9: RYTELO Market Size in France, in USD million (2020-2034)

Table 10: RYTELO Market Size in Italy, in USD million (2020-2034)

Table 11: RYTELO Market Size in Spain, in USD million (2020-2034)

Table 12: RYTELO Market Size in the UK, in USD million (2020-2034)

Table 13: RYTELO Market Size in Japan, in USD million (2020-2034)

List of Figures

Figure 1: RYTELO's Sales Analysis in the 7MM, USD million (2020-2034)

Figure 2: RYTELO Market Size in the United States, USD million (2020-2034)

Figure 3: RYTELO Market Size in Germany, USD million (2020-2034)

Figure 4: RYTELO Market Size in France, USD million (2020-2034)

Figure 5: RYTELO Market Size in Italy, USD million (2020-2034)

Figure 6: RYTELO Market Size in Spain, USD million (2020-2034)

Figure 7: RYTELO Market Size in the United Kingdom, USD million (2020-2034)

Figure 8: RYTELO Market Size in Japan, USD million (2020-2034)

For more information about this report visit https://www.researchandmarkets.com/r/919q8y

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.